Condition
Human Mammary Carcinoma
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 1 (1)
P 2 (1)
Trial Status
Completed4
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05364450Not ApplicableCompleted
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
NCT01118624Phase 2Completed
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
NCT02611544Not ApplicableCompleted
Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
NCT01271738Not ApplicableCompleted
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
NCT00558545Phase 1TerminatedPrimary
A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Showing all 5 trials